Alternatives to oritavancin
1 same-class SPL records vs oritavancin - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Orbactiv
About oritavancin
KIMYRSA is an antibiotic medicine. It is used to treat serious skin infections caused by certain bacteria.
Used for: KIMYRSA treats acute bacterial skin and skin structure infections (ABSSSI) in adults. These infections are caused by specific Gram-positive bacteria. KIMYRSA can fight Staphylococcus aureus, Streptococcus pyogenes, and Enterococcus faecalis, among others. Your doctor will determine if KIMYRSA is the right medicine for your infection.
1 Lipoglycopeptide Antibiotic peers (wide set)
oritavancin vs dalbavancin · FAERS reaction fields
FAERS top-reaction field "Pruritus" shows the widest count spread between oritavancin and dalbavancin in this extract (107-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | oritavancin | dalbavancin |
|---|---|---|
| Pruritus | 162 | 55 |
| Urticaria | 105 | 37 |
| Rash | 84 | 93 |
| Chills | 83 | 22 |
| Back Pain | 81 | 55 |
| Dyspnoea | 74 | 53 |
| Nausea | 67 | 49 |
| Infusion Related Reaction | 60 | 28 |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
oritavancin peer mix vs class inventory
Peer mix
0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for Lipoglycopeptide Antibiotic: 2 drugs.
Frequently Asked Questions
What same-class SPL records sit beside oritavancin? ▼
Reading a wide Lipoglycopeptide Antibiotic peer set (1 records)
oritavancin (Orbactiv) sits in a wide Lipoglycopeptide Antibiotic peer set (1 of 1 class peers shown). Labeled indication field for oritavancin: KIMYRSA treats acute bacterial skin and skin structure infections (ABSSSI) in adults.
Top FAERS reaction fields for oritavancin total 828 reports across 10 reactions, set beside dalbavancin. Counts are exposure-weighted submissions, not per-patient risk.
Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for oritavancin: see also the generic vs brand label guide when reading Orbactiv SPL strings.
Read our methodology - how this data is sourced, computed, and verified.